Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

Key inclusion criteria include:

• Have a current diagnosis of schizophrenia.

• Increase in symptoms over the past 2-4 weeks.

• Willing to remain inpatients for the duration of the trial.

Exclusion Criteria:

• Subjects with a current DSM-IV axis I diagnosis other than schizophrenia

• Subjects who meet the DSM-IV criteria for psychoactive substance abuse and dependence

• Subjects with a history of treatment resistant schizophrenia

• Females of childbearing potential